宫颈癌的细胞免疫治疗：下一代治疗前沿

Cellular Immunotherapy for Cervical Cancer: Next Therapeutics Frontiers.

利用可调控膜结合 IL15 从免疫排斥型软骨肉瘤中生成强效细胞毒性 TIL（肿瘤浸润淋巴细胞）

Potent Cytotoxic Tumor-Infiltrating Lymphocytes Can Be Generated from Immune-Excluded Chondrosarcomas Using Regulatable Membrane-Bound IL15.

探索罕见肿瘤的个体化用药机会与优化 TIL（肿瘤浸润淋巴细胞）治疗：一项基于类器官的神经内分泌肿瘤患者全流程临床映射研究

Discover personalized drug opportunity and optimized tumor-infiltrating lymphocyte therapy for rare cancer: an organoid-based whole-journey clinical m

本研究证实，罕见癌症患者的生存取决于整合的、个体化的伴随诊断与治疗优化。

TIL（肿瘤浸润淋巴细胞）过继细胞治疗的耐药机制

Mechanisms of resistance to adoptive cell therapy with tumor-infiltrating lymphocytes.

TIL-ACT 在特定用途之外显示出前景，但其成功取决于能否克服由患者、肿瘤和产品因素驱动的耐药性。要提高其疗效，需要精细的患者选择、TIL 优化以及机制性见解，以指导新的、改进的治疗方法。

富马酸二甲酯通过激活 mtDNA-cGAS-STING 通路重编程宫颈癌细胞以增强抗肿瘤免疫

Dimethyl fumarate reprograms cervical cancer cells to enhance antitumor immunity by activating mtDNA-cGAS-STING pathway.

该研究阐明，DMF 重编程 CC 细胞以激活 mtDNA-cGAS-STING 通路，进而形成富含趋化因子的微环境，招募 CD8⁺ T 细胞。

过继性 TIL（肿瘤浸润淋巴细胞）治疗宫颈癌的研究进展

Research progress of adoptive tumor infiltrating lymphocyte therapy for cervical cancer.

患者来源结直肠肿瘤类器官与 TIL（肿瘤浸润淋巴细胞）（TILs）共培养体系的建立

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs).

宫颈癌 TIL（肿瘤浸润淋巴细胞）治疗的研究进展

Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer.

宫颈癌免疫治疗的最新进展

Recent advances in immunotherapy for cervical cancer.

宫颈癌转移淋巴结来源的 TIL（肿瘤浸润淋巴细胞）的 T 细胞受体库特征及治疗潜力

T cell receptor repertoire characteristics and therapeutic potential of tumor infiltrating lymphocytes (TILs) derived from metastatic lymph node in ce